Zobrazeno 1 - 10 of 21 pro vyhledávání: '"Sharash Shetty"'
1
Akademický článek
Impact of chronic fibrosing interstitial lung disease on healthcare use: association between fvc decline and inpatient hospitalization
Autor: David Singer, Benjamin Chastek, Andrew Sargent, Jonathan C. Johnson, Sharash Shetty, Craig Conoscenti, Elana J. Bernstein
Publikováno v: BMC Pulmonary Medicine, Vol 23, Iss 1, Pp 1-10 (2023)
Abstract Background Many types of interstitial lung diseases (ILDs) may transition to progressive chronic-fibrosing ILDs with rapid lung function decline and a negative survival prognosis. In real-world clinical settings, forced vital capacity (FVC)
Externí odkaz: https://doaj.org/article/e919b0b08e3d40198bf8d0c0cb27be93
Zobrazit plný text záznamu
2
Cost‐effectiveness analysis of empagliflozin versus sitagliptin as second‐line therapy for treatment in patients with type 2 diabetes in the United States
Autor: Sarah Brand, Sharash Shetty, Odette Reifsnider, Anuraag R. Kansal, Valerie Aponte-Ribero, Pratik Pimple
Publikováno v: Diabetes, Obesity & Metabolism
Aim To estimate the cost‐effectiveness of sequential addition of empagliflozin versus sitagliptin after metformin in patients with type 2 diabetes (T2D) with or without cardiovascular disease (CVD) from the perspective of the US healthcare payer. M
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1efffcd6ff7002ebdb15448a19685ed2
https://doi.org/10.1111/dom.14268
Zobrazit plný text záznamu
3
Cost-effectiveness of second-line empagliflozin versus liraglutide for type 2 diabetes in the United States
Autor: Odette S. Reifsnider, Pratik Pimple, Sarah Brand, Evelien Bergrath Washington, Sharash Shetty, Nihar R. Desai
Publikováno v: Diabetes, obesitymetabolism. 24(4)
To estimate the cost-effectiveness of sequential use of the sodium-glucose co-transporter-2 inhibitor empagliflozin and glucagon-like peptide-1 receptor agonist liraglutide after metformin in patients with type 2 diabetes (T2D) from the US payer pers
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d368ac4c02b80557b7f6ab164a747d04
https://pubmed.ncbi.nlm.nih.gov/34910356
Zobrazit plný text záznamu
5
Healthcare Costs and Resource Utilization Associated with the Use of Empagliflozin Versus Other Antihyperglycemic Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease: A Real-World Retrospective Cohort Analysis
Autor: Aditya Raju, Sharash Shetty, Dana Stafkey-Mailey, Eileen Farrelly, Pratik Pimple
Publikováno v: Diabetes Therapy
Introduction Empagliflozin has demonstrated lower rates of cardiovascular outcomes vs. standard of care among patients with type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD). However, the impact of empagliflozin compared to other brand
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fdd8384a332f77398d1bd16d0a62bba
https://pubmed.ncbi.nlm.nih.gov/34727356
Zobrazit plný text záznamu
6
808-P: Economic Benefits of Initiating Empagliflozin vs. GLP-1 Receptor Agonists among Patients with Type 2 Diabetes
Autor: Aditya Raju, Sharash Shetty, Eileen Farrelly, Pratik Pimple
Publikováno v: Diabetes. 70
Background: SGLT-2 inhibitors and GLP-1 receptor agonists (GLP-1RAs) have proven clinical benefit profiles, and the ADA recommends both as treatment options for T2D patients uncontrolled on metformin. There is limited research on whether these clinic
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8b46dc9852c6b5f11baec5fbc2fda28e
https://doi.org/10.2337/db21-808-p
Zobrazit plný text záznamu
8
1152-P: Effect of Initiating Empagliflozin vs. Glucagon-Like Peptide-1 Receptor Agonists on Health-Care Costs among Patients with Type 2 Diabetes
Autor: Sharash Shetty, Aditya Raju, Pratik Pimple, Dana Stafkey-Mailey
Publikováno v: Diabetes. 69
The 2019 ADA’s Standards of Medical Care in Diabetes recommends use of SGLT2 inhibitor (SGLT2i) or GLP-1 receptor agonist (GLP-1RA) as one of the six drug classes after metformin (MET) in T2D patients, and is recommended as the treatment of choice
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d584b5ea94f0c0403fecdb1011b7a2df
https://doi.org/10.2337/db20-1152-p
Zobrazit plný text záznamu
9
Abstract 232: Initiating Empagliflozin vs. Glucagon-like Peptide 1 Receptor Agonists is Associated With Lower Healthcare Cost of Care Among Patients With Type 2 Diabetes and Cardiovascular Disease
Autor: Pratik Pimple, Sharash Shetty, Dana Stafkey-Mailey, Aditya Raju
Publikováno v: Circulation: Cardiovascular Quality and Outcomes. 13
Background: The 2019 ADA’s Standards of Medical Care in Diabetes recommend use of SGLT-2 inhibitor (SGLT-2i) or GLP-1 receptor agonist (GLP-1RA) as one of the six drug classes after metformin (MET) in type 2 diabetes (T2D) patients, and is recommen
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c0637541b03e333d5b731a1a9a41fdfc
https://doi.org/10.1161/hcq.13.suppl_1.232
Zobrazit plný text záznamu
10
The cost of cardiovascular-disease-related death in patients with type 2 diabetes mellitus
Autor: Sharash Shetty, Angelo Del Parigi, Dana Stafkey-Mailey, Binglin Yue, Weijia Wang, Stephen Sander, Craig I Coleman, Anna D. Coutinho
Publikováno v: Current Medical Research and Opinion. 34:1081-1087
To assess the magnitude of difference in all-cause healthcare resource utilization (HCRU) and costs between patients with type 2 diabetes mellitus (T2DM) who died from a cardiovascular disease (CVD)-related cause in the year preceding death vs. those
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e8d8880213369494f26a60953d7724d
https://doi.org/10.1080/03007995.2018.1445620
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje